Subscribe by Email

About the Blog

The Active Ingredient features expert insights and commentary from leaders of ZS Associates' global pharmaceuticals practice.

Search by Topic

see all

If We Pull the Plug on Drug Rebates, Can We Finally Focus on Value?

Posted by Pratap Khedkar on Thu, Oct 18, 2018


As more healthcare stakeholders clamor for price transparency, prescription drug rebates’ days could be numbered. Whether the behind-the-scenes negotiation tool—which has been linked to a growing discrepancy between a drug’s list and net prices—will partially or completely disappear is up for debate, but one certainty at this point is that the price transparency knock rarely goes unanswered.

Read More

Topics: patient outcomes, Bill Coyle, Pratap Khedkar, Drug pricing, Howard Deutsch, pharma companies, rebates, product value

Trump’s Drug Pricing Plan: What Does it Really Mean for Pharma?

Posted by Pratap Khedkar on Thu, May 17, 2018

Howard Deutsch co-authored this blog post with Pratap Khedkar.

President Donald Trump and HHS Secretary Alex Azar addressed the nation from the White House Rose Garden last week, introducing American Patients First, a drug pricing plan that Pres. Trump described as the “most sweeping action in history to lower the price of prescription drugs.” Let’s take a closer look, shall we?

Read More

Topics: Medicare, Pratap Khedkar, Drug pricing, Howard Deutsch, value-based pricing, price transparency, pharma companies, rebates

Subscribe to The Active Ingredient


Subscribe to receive email notifications whenever new blog posts are published.